EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Novel size-adjustable pulmonary valve US early feasibility study: One-year outcomes

Mark E Galantowicz, Corey A Stiver, Oliver M Barry, Emile A Bacha, Kanwal M Farooqi, Gerald R Marx, Diego Porras, Christopher W Baird, Aimee K Armstrong

The Journal of Thoracic and Cardiovascular Surgery · 2025

DOI: 10.1016/j.jtcvs.2025.07.035 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Journal of Thoracic and Cardiovascular Surgery, 2025. Verfasst von Mark E Galantowicz und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiothoracic Surgery, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio. Electronic address: Mark.Galantowicz…. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Heart Valve Prosthesis Implantation, Pulmonary Valve, Pulmonary Valve Insufficiency. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: The Autus Size-Adjustable Valve (ASAV) is a novel surgically implanted fully synthetic expandable pulmonary valve designed for pediatric patients. This first-in-human study evaluated initial device feasibility and safety. METHODS: This was a Food and Drug Administration-approved prospective, single-arm, multicenter Investigational Device Exemption Early Feasibility Study to evaluate safety and preliminary effectiveness of the ASAV in pediatric patients aged 18 months to 16 years who require pulmonary valve replacement. All potential subjects underwent review by a screening committee to determine eligibility. Subjects had pre- and postoperative evaluation via transthoracic echocardiography. One-year outcomes are reported. RESULTS: Eleven subjects (9 male) were enrolled at 3 centers. Median age at implant was 8.2 years (range, 2.7-13.9) years and body surface area ranged from 0.6 to 1.3 m2. The ASAV was size-adjusted at implant in all subjects, ranging from 14 mm to 20 mm internal diameter (z score -1 to +1). Median hospital length of stay was 4 (range, 3-5) days. There was no mortality, and 100% of subjects were free from device-related adverse events. No thrombus was observed. No subject developed endocarditis. At 1-year follow-up, 10 (90.9%) subjects had no pulmonary regurgitation (1 subject [8.1%] had trivial pulmonary regurgitation), and the mean right ventricle-pulmonary artery pressure gradient was 16 ± 6 mm Hg. CONCLUSIONS: One-year results of the novel ASAV Early Feasibility Study demonstrated intact valve function and no device-related adverse events. The ASAV is now under evaluation in an Investigational Device Exemption pivotal study.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve ProsthesisHeart Valve Prosthesis ImplantationPulmonary ValvePulmonary Valve InsufficiencyAdolescentChildChild, PreschoolFemaleHumansMaleFeasibility StudiesProspective StudiesProsthesis DesignTime FactorsTreatment OutcomeUnited States

Stichwörter der Autor:innen

congenitalfeasibility studypediatricpulmonary valvesize-adjustable

Autor:innen und Institutionen

  • Department of Cardiothoracic Surgery, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio. Electronic address: Mark.Galantowicz@nationwidechildrens.org.
  • The Heart Center, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.
  • Division of Pediatric Cardiology, New York-Presbyterian Hospital/Columbia University Medical Center, New York, NY.
  • Division of Cardiac, Thoracic, and Vascular Surgery, New York-Presbyterian/Columbia University Medical Center, New York, NY.
  • Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, Mass.
  • Department of Cardiac Surgery, Boston Children's Hospital, Harvard Medical School, Boston, Mass.

Zitieren

APA

Galantowicz, M. E., Stiver, C. A., Barry, O. M., Bacha, E. A., Farooqi, K. M., Marx, G. R., Porras, D., Baird, C. W., & Armstrong, A. K. (2025). Novel size-adjustable pulmonary valve US early feasibility study: One-year outcomes. The Journal of Thoracic and Cardiovascular Surgery. https://doi.org/10.1016/j.jtcvs.2025.07.035

Vancouver

Galantowicz ME, Stiver CA, Barry OM, Bacha EA, Farooqi KM, Marx GR, et al. Novel size-adjustable pulmonary valve US early feasibility study: One-year outcomes. The Journal of Thoracic and Cardiovascular Surgery. 2025. doi:10.1016/j.jtcvs.2025.07.035

BibTeX
@article{Galantowicz2025,
  author = {Galantowicz, Mark E and Stiver, Corey A and Barry, Oliver M and Bacha, Emile A and Farooqi, Kanwal M and Marx, Gerald R and Porras, Diego and Baird, Christopher W and Armstrong, Aimee K},
  title = {Novel size-adjustable pulmonary valve US early feasibility study: One-year outcomes},
  journal = {The Journal of Thoracic and Cardiovascular Surgery},
  year = {2025},
  doi = {10.1016/j.jtcvs.2025.07.035}
}
Kostenlos starten →